| ID | 1038 |
| Name of the vaccine | Vaxelis |
| Microbe | Bacteria |
| Disease name | Pertussis (Whooping Cough) |
| Name of bacteria | Bordetella pertussis |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 6 weeks to 4 years |
| Description of the vaccine | Diphtheria, tetanus toxoids, acellular pertussis, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine (DTaP vaccine). |
| Name of the manufacturer | Sanofi Pasteur Limited |
| Name of the manufacturing country | Canada |
| Year of manufacture | 2018 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Three doses administered at 2, 4, and 6 months. |
| Mechanism of action | Not clearly defined. |
| Route of administration | Intramuscular |
| Indications | Prevents diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b. |
| Export | Distributed by - Merck Sharp & Dohme Corp and Sanofi Pasteur Inc., USA |
| Approval | Thailand FDA |
| Adjuvant | Aluminium salts |
| Repurposing | Also for tetanus, diphtheria, polio, Hib (Haemophilus influenzae type b), and hepatitis B. |
| Side effects of vaccine | Irritability, crying , injection site pain, erythema and swelling, somnolence, decreased appetite, fever and vomiting. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/119465/download |
| Other name | NA |
| Additional Links | NA
|